AWM Investment Company Inc. purchased a new position in Aquestive Therapeutics, Inc. (NASDAQ: AQST)

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Aquestive Therapeutics (NASDAQ:AQST

Aquestive Therapeutics, Inc. (AQST) Q2 2026 Earnings Call Transcript

Aquestive Therapeutics NASDAQ: AQST said it plans to resubmit its new drug application for Anaphylm,

Aquestive Therapeutics (AQST) came out with a quarterly loss of $0.18 per share versus the Zacks Con

Aquestive Therapeutics (NASDAQ:AQST) affirms FY2026 sales outlook from $46.000 million-$50.000 milli

WARREN, N.J., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) ("Aquest

Aquestive Therapeutics Inc. (NASDAQ:AQST) announced positive findings from human factors and pharmac

Aquestive Therapeutics reports positive study results for Anaphylm sublingual film, paving the way f

BWMN gained 55.1%, HZO rose 45.8%, ABCL gained 35.6%, SLN rose 34.3%, ACHR gained 19.5%, NESR gained

Human factors and clinical study results support planned resubmission of Anaphylm™ NDA in the third

WARREN, N.J., July 29, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquest

WARREN, N.J., July 07, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquesti

Aquestive Therapeutics (AQST) was a big mover last session on higher-than-average trading volume. Th

Aquestive Therapeutics, Inc. (AQST) Q1 2026 Earnings Call Transcript

Aquestive Therapeutics NASDAQ: AQST said it remains on track to resubmit its new drug application fo

U.S. stocks rose, with Dow Jones up 300 points. STAA shares surged after better-than-expected result

While the top- and bottom-line numbers for Aquestive Therapeutics (AQST) give a sense of how the bus

Aquestive Therapeutics (AQST) came out with a quarterly loss of $0.07 per share versus the Zacks Con

Aquestive Therapeutics (NASDAQ:AQST) affirms FY2026 sales outlook from $46.000 million-$50.000 milli

Aquestive Therapeutics (NASDAQ:AQST) reported quarterly losses of $(0.07) per share which beat the a

WARREN, N.J., May 13, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) ("Aquesti

WARREN, N. J. , May 12, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) ("Aques

WARREN, N.J., May 06, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquesti

NEW YORK--(BUSINESS WIRE)---- $AQST #AQST--Faruqi & Faruqi, LLP, a leading national securities law f

NEW YORK, May 04, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recogniz

Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmac

Aquestive Therapeutics (NASDAQ:AQST) sees FY2026 sales of $46.000 million-$50.000 million vs $49.888

Aquestive Therapeutics (NASDAQ:AQST) reported quarterly losses of $(0.15) per share which missed the

Aquestive received an FDA rejection for its allergy film due to safety and use issues. The company p

Deficiencies limited to packaging and administration Company believes it can rapidly resolve defi

Benzinga examined the prospects for many investors' favorite stocks over the last week — here&#3

ARS Pharmaceuticals Inc. stock rose Friday as FDA identified deficiencies in rival Aquestive's a

Aquestive Therapeutics shares fall after the FDA flags deficiencies in its Anaphylm allergy drug app

Announces receipt of FDA letter stating it has identified deficiencies that preclude labeling discus